search
Back to results

Brain-controlled Spinal Cord Stimulation in Patients With Spinal Cord Injury (STIMO-BSI)

Primary Purpose

Spinal Cord Injuries

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
STIMO-BSI system implantation
Sponsored by
Ecole Polytechnique Fédérale de Lausanne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injuries

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Having completed the main phase of the STIMO study (NCT02936453).
  • SCI graded as American Spinal Injury Association Impairment Scale (AIS) A, B, C & D
  • Level of lesion: T10 and above, based on AIS level determination by the PI, with preservation of conus function
  • The intact distance between the cone and the lesion must be at least 60 mm.
  • Focal spinal cord disorder caused by either trauma or epidural, subdural or intramedullary bleeding
  • Minimum 12 months post-injury
  • Completed in-patient rehabilitation program
  • Stable medical, physical and psychological condition as considered by Investigators
  • Able to understand and interact with the study team in French or English
  • Adequate care-giver support and access to appropriate medical care in patient's home community
  • Must agree to comply in good faith with all conditions of the study and to attend all required study training and visit
  • Must provide and sign the Informed Consent prior to any study related procedures

Exclusion Criteria:

  • Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders)
  • History of severe autonomic dysreflexia
  • Brain damage
  • Epilepsy
  • Spinal stenosis
  • Use of an intrathecal Baclofen pump.
  • Any active implanted cardiac device such as pacemaker or defibrillator.
  • Any indication that would require diathermy.
  • Any indication that would require MRI.
  • Increased risk for defibrillation.
  • Severe joint contractures disabling or restricting lower limb movements.
  • Haematological disorders with increased risk for surgical interventions (increased risk of haemorrhagic events).
  • Congenital or acquired lower limb abnormalities (affection of joints and bone).
  • Women who are pregnant (pregnancy test obligatory for women of childbearing potential) or breast feeding or not willing to take contraception.
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Spinal cord lesion due to either a neurodegenerative disease or a tumor.
  • Gastrointestinal ulcers in the last five years
  • Known or suspected eye disorders or diseases
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
  • Any other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results

Sites / Locations

  • CHUV

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

All participants

Arm Description

All participants receive the same intervention.

Outcomes

Primary Outcome Measures

Safety Measure
Number of Adverse Events possibly, probably or causally related to the procedure or device.
Safety Measure
Number of device deficiencies

Secondary Outcome Measures

WISCI II score
From 0 to 20, higher scores mean a better outcome
10mWT
Weight bearing capacity
SCIM III score
From 0 to 100, higher scores mean a better outcome
6minWT
Time Up and Go
Maximum Voluntary Contraction
ASIA score
From 0 to 100, higher scores mean a better outcome
Modified Ashworth Scale
From 0 to 4, higher scores mean a worst outcome
Berg Balance Scale
From 0 to 56, higher scores mean a better outcome
Gait Analysis
Average step height, step length, amplitude of EMG activity during walking
WHOQOL-BREF
From 0 to 100, higher scores mean a better outcome
BCI performance measures
Decoding accuracy from 0-100% higher numbers mean a better outome
Upper Limb Neurobiomechanics
Average range of movement, amplitude of EMG activity during upper limb movements
ECoG signal stability
Power density spectrum of the ECoG signal over each electrode
SSEP
Amplitude and latency of the cortically evoked potentials

Full Information

First Posted
November 5, 2020
Last Updated
November 4, 2021
Sponsor
Ecole Polytechnique Fédérale de Lausanne
search

1. Study Identification

Unique Protocol Identification Number
NCT04632290
Brief Title
Brain-controlled Spinal Cord Stimulation in Patients With Spinal Cord Injury
Acronym
STIMO-BSI
Official Title
Brain-controlled Spinal Cord Stimulation in Patients With Spinal Cord Injury
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Enrolling by invitation
Study Start Date
July 4, 2021 (Actual)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
August 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ecole Polytechnique Fédérale de Lausanne

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In a current first-in-human study, called Stimulation Movement Overground (STIMO, NCT02936453), Epidural Electrical Stimulation (EES) of the spinal cord is applied to enable individuals with chronic severe spinal cord injury (SCI) to complete intensive locomotor neurorehabilitation training. In this clinical feasibility study, it was demonstrated that EES results in an immediate enhancement of walking function, and that when applied repeatedly as part of a neurorehabilitation program, EES can improve leg motor control and trigger neurological recovery in individuals with severe SCI to a certain extent (Wagner et al. 2018). Preclinical studies showed that linking brain activity to the onset and modulation of spinal cord stimulation protocols not only improves the usability of the stimulation, but also augments neurological recovery. Indeed, rats rapidly learned to modulate their cortical activity in order to adjust the amplitude of spinal cord stimulation protocols. This brain-spine interface allowed them to increase the amplitude of the movement of their otherwise paralyzed legs to climb up a staircase (Bonizzato et al. 2018). Moreover, gait rehabilitation enabled by this brain-spine interface (BSI) augmented plasticity and neurological recovery. When EES was correlated with cortical neuron activity during training, rats showed better recovery than when training was only supported by continuous stimulation (Bonizzato et al. 2018). This concept of brain spine-interface was validated in non-human primates (Capogrosso et al. 2016). Clinatec (Grenoble, France) has developed a fully implantable electrocorticogram (ECoG) recording device with a 64-channel epidural electrode array capable of recording electrical signals from the motor cortex for an extended period of time and with a high signal to noise ratio the electrical signals from the motor cortex. This ECoG-based system allowed tetraplegic patients to control an exoskeleton (ClinicalTrials.gov, NCT02550522) with up to 8 degrees of freedom for the upper limb control (Benabid et al. 2019). This device was implanted in 2 individuals so far; one of them has been using this system both at the hospital and at home for more than 3 years. We hypothesize that ECoG-controlled EES in individuals with SCI will establish a direct bridge between the patient's motor intention and the spinal cord below the lesion, which will not only improve or restore voluntary control of leg movements, but will also boost neuroplasticity and neurological recovery when combined with neurorehabilitation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
All participants
Arm Type
Experimental
Arm Description
All participants receive the same intervention.
Intervention Type
Device
Intervention Name(s)
STIMO-BSI system implantation
Intervention Description
Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
Primary Outcome Measure Information:
Title
Safety Measure
Description
Number of Adverse Events possibly, probably or causally related to the procedure or device.
Time Frame
Through study completion, an average of 1 year
Title
Safety Measure
Description
Number of device deficiencies
Time Frame
Through study completion, an average of 1 year
Secondary Outcome Measure Information:
Title
WISCI II score
Description
From 0 to 20, higher scores mean a better outcome
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
10mWT
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
Weight bearing capacity
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
SCIM III score
Description
From 0 to 100, higher scores mean a better outcome
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
6minWT
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
Time Up and Go
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
Maximum Voluntary Contraction
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
ASIA score
Description
From 0 to 100, higher scores mean a better outcome
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
Modified Ashworth Scale
Description
From 0 to 4, higher scores mean a worst outcome
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
Berg Balance Scale
Description
From 0 to 56, higher scores mean a better outcome
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
Gait Analysis
Description
Average step height, step length, amplitude of EMG activity during walking
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
WHOQOL-BREF
Description
From 0 to 100, higher scores mean a better outcome
Time Frame
1 week before implantation, 8 weeks and 19 weeks after implantation
Title
BCI performance measures
Description
Decoding accuracy from 0-100% higher numbers mean a better outome
Time Frame
8 weeks and 19 weeks after implantation
Title
Upper Limb Neurobiomechanics
Description
Average range of movement, amplitude of EMG activity during upper limb movements
Time Frame
8 weeks and 19 weeks after implantation
Title
ECoG signal stability
Description
Power density spectrum of the ECoG signal over each electrode
Time Frame
8 weeks and 19 weeks after implantation
Title
SSEP
Description
Amplitude and latency of the cortically evoked potentials
Time Frame
8 weeks and 19 weeks after implantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Having completed the main phase of the STIMO study (NCT02936453). SCI graded as American Spinal Injury Association Impairment Scale (AIS) A, B, C & D Level of lesion: T10 and above, based on AIS level determination by the PI, with preservation of conus function The intact distance between the cone and the lesion must be at least 60 mm. Focal spinal cord disorder caused by either trauma or epidural, subdural or intramedullary bleeding Minimum 12 months post-injury Completed in-patient rehabilitation program Stable medical, physical and psychological condition as considered by Investigators Able to understand and interact with the study team in French or English Adequate care-giver support and access to appropriate medical care in patient's home community Must agree to comply in good faith with all conditions of the study and to attend all required study training and visit Must provide and sign the Informed Consent prior to any study related procedures Exclusion Criteria: Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders) History of severe autonomic dysreflexia Brain damage Epilepsy Spinal stenosis Use of an intrathecal Baclofen pump. Any active implanted cardiac device such as pacemaker or defibrillator. Any indication that would require diathermy. Any indication that would require MRI. Increased risk for defibrillation. Severe joint contractures disabling or restricting lower limb movements. Haematological disorders with increased risk for surgical interventions (increased risk of haemorrhagic events). Congenital or acquired lower limb abnormalities (affection of joints and bone). Women who are pregnant (pregnancy test obligatory for women of childbearing potential) or breast feeding or not willing to take contraception. Known or suspected non-compliance, drug or alcohol abuse. Spinal cord lesion due to either a neurodegenerative disease or a tumor. Gastrointestinal ulcers in the last five years Known or suspected eye disorders or diseases Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) Any other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jocelyne Bloch
Organizational Affiliation
Centre Hospitalier Universitaire Vaudois
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHUV
City
Lausanne
State/Province
Vaud
ZIP/Postal Code
1011
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30382197
Citation
Wagner FB, Mignardot JB, Le Goff-Mignardot CG, Demesmaeker R, Komi S, Capogrosso M, Rowald A, Seanez I, Caban M, Pirondini E, Vat M, McCracken LA, Heimgartner R, Fodor I, Watrin A, Seguin P, Paoles E, Van Den Keybus K, Eberle G, Schurch B, Pralong E, Becce F, Prior J, Buse N, Buschman R, Neufeld E, Kuster N, Carda S, von Zitzewitz J, Delattre V, Denison T, Lambert H, Minassian K, Bloch J, Courtine G. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018 Nov;563(7729):65-71. doi: 10.1038/s41586-018-0649-2. Epub 2018 Oct 31.
Results Reference
background
PubMed Identifier
27830790
Citation
Capogrosso M, Milekovic T, Borton D, Wagner F, Moraud EM, Mignardot JB, Buse N, Gandar J, Barraud Q, Xing D, Rey E, Duis S, Jianzhong Y, Ko WK, Li Q, Detemple P, Denison T, Micera S, Bezard E, Bloch J, Courtine G. A brain-spine interface alleviating gait deficits after spinal cord injury in primates. Nature. 2016 Nov 10;539(7628):284-288. doi: 10.1038/nature20118.
Results Reference
background
PubMed Identifier
31587955
Citation
Benabid AL, Costecalde T, Eliseyev A, Charvet G, Verney A, Karakas S, Foerster M, Lambert A, Moriniere B, Abroug N, Schaeffer MC, Moly A, Sauter-Starace F, Ratel D, Moro C, Torres-Martinez N, Langar L, Oddoux M, Polosan M, Pezzani S, Auboiroux V, Aksenova T, Mestais C, Chabardes S. An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration. Lancet Neurol. 2019 Dec;18(12):1112-1122. doi: 10.1016/S1474-4422(19)30321-7. Epub 2019 Oct 3.
Results Reference
background
PubMed Identifier
30068906
Citation
Bonizzato M, Pidpruzhnykova G, DiGiovanna J, Shkorbatova P, Pavlova N, Micera S, Courtine G. Brain-controlled modulation of spinal circuits improves recovery from spinal cord injury. Nat Commun. 2018 Aug 1;9(1):3015. doi: 10.1038/s41467-018-05282-6.
Results Reference
background

Learn more about this trial

Brain-controlled Spinal Cord Stimulation in Patients With Spinal Cord Injury

We'll reach out to this number within 24 hrs